We also examined our database for other, non-CRC malignancies harboring A59T mutations in KRAS. We detected 36 additional cases of A59T variants in tumors from patients with other cancers, including most prominently in endometrial, gastroesophageal, and ovarian carcinomas (Table 5). This evidence concerns the gene KRAS and ovarian carcinoma.